Please complete the CAPTCHA to continue
@exterapartners.com
✓
2 phones found area 617
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
B. Christopher Kim is listed as Executive at Bridge Biotherapeutics at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주), based in Boston, Massachusetts, United States. AeroLeads shows a work email signal at exterapartners.com, phone signal with area code 617, and a matched LinkedIn profile for B. Christopher Kim.
B. Christopher Kim previously worked as EVP, Board Member at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주) and Advisor at Curie.Bio. B. Christopher Kim holds Mba, Finance, Entrepreneurship from Carnegie Mellon University - Tepper School Of Business.
This section adds company-level context without repeating B. Christopher Kim's masked contact details.
AeroLeads found 1 current-domain work email signal for B. Christopher Kim. Compare company email patterns before reaching out.
Life sciences company building, team building and making investments.
Listed skills include Venture Capital, Biotechnology, Entrepreneurship, Corporate Development, and 15 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Seongnam-si, Gyeung-gi Do, KR
- Lead Boston Discovery Center (BDC), partnership with the Baran and Cravatt labs at Scripps, and corporate- and business development- Helped close €1.1B licensing deal w Boehringer Ingelheim for Bridge's PI autotaxin inhibitor for IPF, one of the largest biotech deals in Korea- Bridge is a clinical stage biotech company developing first-in-class or.
Basel, BS, CH
- Serve on venture Selection Committee. BaseLaunch is an accelerator located in one of the most active life sciences hubs in Europe. Since its founding in 2018, BL has supported seed-stage ventures that have since raised over $550M. Other selection committee members are represented by global big pharma, leading biotech and VCs.
Pittsburgh, PA, US
Lipella is a clinical-stage biotech company developing drugs as supportive care for cancer survivors and for orphan indications. Its first product candidate LP-10, which utilizes Lipella’s proprietary drug delivery platform, is currently in P2 clinical study to treat bleeding and pain in hemorrhagic cystitis of the bladder.
Boston, Massachusetts, US
- FMI operates on first-in-class platform/strategy to source, evaluate and invest in early-stage biotech companies
Toronto, ON, CA
- Private partnership and investment platform for like-minded partners
- Responsible for all aspects of launching, investment, portfolio support and the Fund operations- KSLSF (www.kslsfund.com) is a cross-Pacific venture capital fund which invests in and supports emerging life sciences companies in S. Korea and the US; KSLSF was founded as partnership between Oxford Bioscience Partners of the US (later, spun off KSLSF as an.
KR
- Advise BD, corporate development and R&D portfolio strategies; CKD is a top-5 pharma company in Korea
Tel Aviv, IL
- Served as the first independent board member- CytoReason is an AI-enabled biotechnology company focused on data analytics and target discovery with expertise in immunology; CytoReason has signed partnership with multiple big pharmas.
- PharmAbcine is a clinical stage oncology company, went public KOSDAQ:208340
- Oxford Bioscience Partners is a venture capital firm that provides equity financing and management assistance to entrepreneurial-driven companies within the life sciences and healthcare sectors; the firm has invested in over 140 life science companies worldwide and has an AUM $1B
Various consulting and advisory including for Leerink, a Puretech portfolio, etc.
Basel, Baselstadt, CH
- Led corporate development, strategy and operations of NIBR and Global BioMarker Development Group (served as Global Head & Associate Director)- The Novartis Institutes for BioMedical Research is the global pharmaceutical research organization of Novartis; headquartered in Cambridge, USA, and with ~5,000 scientists and physicians around the world, it is.
Armonk, New York, NY, US
- Developed blueprint to support Emerging Business Opportunities initiative of IBM Healthcare and Life Sciences- The Extreme Blue™ program is IBM's premier program for people pursuing software development or business degrees
Houston, TX, US
- Conducted PhD graduate biomedical research in developmental biology using mouse genetics and transgenic approaches; published two leading/co-leading publications- MD Anderson is a comprehensive cancer center and is ranked the top cancer hospital in the US
Quick answers generated from the profile data available on this page.
B. Christopher Kim works for Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주).
B. Christopher Kim is listed as Executive at Bridge Biotherapeutics at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주).
AeroLeads has found 1 work email signal at @exterapartners.com for B. Christopher Kim at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주).
AeroLeads has found 2 phone signal(s) with area code 617 for B. Christopher Kim at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주).
B. Christopher Kim is based in Boston, Massachusetts, United States while working with Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주).
B. Christopher Kim has worked for Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주), Curie.Bio, Baselaunch, Lipella Pharmaceuticals, and Freemind Investments | A Venture Capital Fund.
You can use AeroLeads to view verified contact signals for B. Christopher Kim at Bridge Biotherapeutics, Inc. 브릿지바이오테라퓨틱스(주), including work email, phone, and LinkedIn data when available.
B. Christopher Kim holds Mba, Finance, Entrepreneurship from Carnegie Mellon University - Tepper School Of Business.
B. Christopher Kim is listed with skills including Venture Capital, Biotechnology, Entrepreneurship, Corporate Development, Strategy, Drug Development, Finance, and Investments.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts